You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 146 No. 12, December 1986 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ORIGINAL INVESTIGATIONS
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (8)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Relative Efficacy and Toxicity of Netilmicin and Tobramycin in Oncology Patients

Jack M. Bernstein, MD; Geoffrey J. Gorse, MD; M. Ines Linzmayer, MD; P. Samuel Pegram, MD; Robert D. Levin, MD; Robert E. Brummett, PhD; Norman Markowitz, MD; Louis D. Saravolatz, MD; Richard R. Lorber, MD

Arch Intern Med. 1986;146(12):2329-2334.


Abstract



• We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections. The two treatment regimens were equally efficacious. Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin 17% vs 11%). Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin—treated patients. Of those evaluated with posttherapy audiograms, three of four netilmicin and piperacillin—treated patients had auditory thresholds return to baseline compared with one of nine tobramycin and piperacillin—treated patients. The number of ≥15-dB increases in auditory threshold as a proportion of total ≥15-dB changes (increases and decreases) was significantly lower in netilmicin and piperacillin— vs tobramycin and piperacillin—treated patients (18 of 78 vs 67 of 115). We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than



Author Affiliations



From the Section of Infectious Disease, Marshall University School of Medicine and Huntington Veterans Administration Medical Center, Huntington, WV (Drs Bernstein and Gorse); the Pharmaceutical Research Division, Schering-Plough Corp, Kenilworth, NJ (Drs Linzmayer and Lorber); the Department of Medicine, Bowman Gray School of Medicine, Winston-Salem, NC (Dr Pegram); the Division of Hematology and Oncology, Mount Sinai Hospital, Chicago (Dr Levin); the Department of Otolaryngology, The Oregon Health Sciences University, Portland (Dr Brummett); and the Division of Infectious Diseases and Hospital Epidemiology, Henry Ford Hospital, Detroit (Drs Markowitz and Saravolatz). Dr Bernstein is currently with the Veterans Administration Medical Center, Dayton, Ohio.


Footnotes



Accepted for publication April 2, 1986.

Reprint requests to Section of Infectious Diseases, Marshall University School of Medicine, Huntington, WV 25701 (Dr Gorse).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Ciprofloxacin plus Piperacillin Compared with Tobramycin plus Piperacillin as Empirical Therapy in Febrile Neutropenic Patients: A Randomized, Double-Blind Trial
Peacock et al.
ANN INTERN MED 2002;137:77-87.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.